Literature DB >> 23298761

Colonoscopic perforations in inflammatory bowel disease: a retrospective study in a French referral centre.

Anthony Buisson1, Jean-Baptiste Chevaux, Hervé Hudziak, Laurent Bresler, Marc-André Bigard, Laurent Peyrin-Biroulet.   

Abstract

BACKGROUND: Whether inflammatory bowel disease patients are at increased risk of colonoscopic perforations remains controversial. Aim of this study was to investigate whether these patients are at increased risk of perforations.
METHODS: Electronic charts of all patients enrolled in the Nancy IBD cohort (1999-2012) were reviewed. All non-inflammatory bowel disease patients who underwent colonoscopy (1999-2012) were used as controls.
RESULTS: Of 17,992 colonoscopies, 2375 (13.2%) were performed for inflammatory bowel disease: 1547 for Crohn's disease and 828 for ulcerative colitis. Four IBD patients (0.168%) experienced perforation. Perforation occurred in the sigmoid colon (n = 3) and right colon (n = 1) during disease monitoring or colonic stenosis dilatation. Three patients underwent surgery (2 stomas and no death). Colonoscopic perforation occurred in 16/15,617 controls (0.102%): colonic cancer diagnosis (n = 5, 31.3%) or dilatation (n = 2, 12.5%), polypectomy (n = 5, 31.3%) or mucosectomy (n = 1, 6.3%), and follow-up after diverticulitis (n = 2, 12.5%). Perforation rate was not different between IBD and controls (p = 0.57). Perforations occurred in the sigmoid colon (n = 10, 62.5%), the right colon (n = 4, 25%) and the rectum (n = 2, 12.5%). Twelve controls underwent surgery (9 stomas and one death).
CONCLUSION: In this referral centre-based cohort, inflammatory bowel disease patients were not at increased risk of colonoscopic perforation compared to non-IBD controls.
Copyright © 2012 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23298761     DOI: 10.1016/j.dld.2012.11.012

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  6 in total

1.  Bowel wall healing assessed using magnetic resonance imaging predicts sustained clinical remission and decreased risk of surgery in Crohn's disease.

Authors:  Anthony Buisson; Constance Hordonneau; Felix Goutorbe; Christophe Allimant; Marion Goutte; Maud Reymond; Bruno Pereira; Gilles Bommelaer
Journal:  J Gastroenterol       Date:  2018-08-30       Impact factor: 7.527

2.  Faecal calprotectin and magnetic resonance imaging in detecting Crohn's disease endoscopic postoperative recurrence.

Authors:  Pierre Baillet; Guillaume Cadiot; Marion Goutte; Felix Goutorbe; Hedia Brixi; Christine Hoeffel; Christophe Allimant; Maud Reymond; Hélène Obritin-Guilhen; Benoit Magnin; Gilles Bommelaer; Bruno Pereira; Constance Hordonneau; Anthony Buisson
Journal:  World J Gastroenterol       Date:  2018-02-07       Impact factor: 5.742

3.  Detection and characterization of murine colitis and carcinogenesis by molecularly targeted contrast-enhanced ultrasound.

Authors:  Markus Brückner; Jan Heidemann; Tobias M Nowacki; Friederike Cordes; Jörg Stypmann; Philipp Lenz; Faekah Gohar; Andreas Lügering; Dominik Bettenworth
Journal:  World J Gastroenterol       Date:  2017-04-28       Impact factor: 5.742

4.  Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study.

Authors:  Natsuki Ishida; Masanao Kaneko; Yusuke Asai; Takahiro Miyazu; Satoshi Tamura; Shinya Tani; Mihoko Yamade; Moriya Iwaizumi; Yasushi Hamaya; Satoshi Osawa; Takahisa Furuta; Ken Sugimoto
Journal:  BMC Gastroenterol       Date:  2022-09-15       Impact factor: 2.847

5.  C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis.

Authors:  Natsuki Ishida; Tomohiro Higuchi; Takahiro Miyazu; Satoshi Tamura; Shinya Tani; Mihoko Yamade; Moriya Iwaizumi; Yasushi Hamaya; Satoshi Osawa; Takahisa Furuta; Ken Sugimoto
Journal:  Sci Rep       Date:  2021-06-14       Impact factor: 4.379

6.  Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.

Authors:  Luca Pio Stoppino; Nicola Della Valle; Stefania Rizzi; Elsa Cleopazzo; Annarita Centola; Donatello Iamele; Christos Bristogiannis; Giuseppe Stoppino; Roberta Vinci; Luca Macarini
Journal:  BMC Med Imaging       Date:  2016-05-05       Impact factor: 1.930

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.